Objective To summarize the clinical characteristics and analyze prognostic factors of neuroblastoma (NB) in infants (≤12 months) at a single center. Methods A retrospective analysis was conducted on the clinical data of infant patients (≤12 months) diagnosed with NB and treated between January 2014 and December 2022. Clinical features were analyzed, and comparisons between two sample rates were performed using the χ² test. Univariate prognostic analysis was conducted using the log-rank test, and survival outcomes were analyzed using the Kaplan-Meier method. Results A total of 42 infants (≤12 months) with NB were enrolled. Low-risk patients underwent surgical resection alone; intermediate-risk patients received surgery combined with chemotherapy with or without maintenance therapy; high-risk patients were treated with surgery and chemotherapy with or without maintenance therapy or radiotherapy. The 5-year event-free survival (EFS) rate was (92.7±4.9)%, and the 5-year overall survival rate was (95.2±3.6)%. Only two patients died because of tumor recurrence or progression. Univariate analysis identified MYCN amplification and the initial lactate dehydrogenase (LDH) level ≥ five times the upper limit of the normal were significantly associated with poor prognosis (5-year EFS: 33.3% vs. 97.4% and 60.0% vs. 97.3%, P<0.0001 and P=0.0035). Conclusion Infant NB has a favorable overall prognosis. MYCN amplification and markedly elevated initial LDH are associated with poor outcomes.

Objective: To systematically analyze the confirmatory positivity of different combinations of HBsAg screening results in blood testing, providing data to support the optimization of blood donor eligibility management. Methods: A retrospective analysis was conducted on blood screening data from 174 266 voluntary blood donor samples at the Chongqing Blood Center between October 2021 and September 2022. Samples with inconsistent results between the two HBsAg enzymelinked immunosorbent assays (ELISA) and individual donor nucleic acid testing (NAT) were confirmed using an electrochemiluminescence immunoassay (ECLIA) and a neutralization test. The detection efficacy of four different HBsAg ELISA reagents was compared using the HBsAg-confirmed positive samples. Results: A total of 767(0.44%) HBV-reactive (HB-sAg and/or HBV DNA reactive) samples were detected. Among them, 344 samples with discordant serological and NAT results were collected, of which 64(18.6%) were confirmed positive by neutralization test. Additionally, 5 samples that were neutralization-negative but double-reactive for HBsAg and HBV DNA were confirmed as positive according to FDA guidance, resulting in a total of 69(20.1%) confirmed HBsAg-positive samples. There were significant differences in the neutralization test confirmation rates among different screening result categories (P<0.05): The group with dual HBsAg reagent reactivity (double reactive) & NAT-negative had the highest confirmation rate (96.9%, 31/32); the group reactive to only reagent 2 (single reactive) had a rate of 25.7% (29/113); while the confirmation rates for samples reactive to only reagent 1 and samples with isolated HBV DNA positivity were extremely low [0(0/34) and 2.4%(4/165), respectively]. The four commercial reagents showed significant differences in their ability to detect confirmed positive samples that were initially single reactive (P<0.05). Conclusion: Given the performance variations among HBsAg screening reagents, thorough performance verification is essential before implementation. When NAT is negative, dual HBsAg reactivity in screening can serve as a basis for confirming infection and directly deferring blood donors. However, confirming infection in donors with single HBsAg reactivity is more challenging, necessitating supplementary tests to rule out infection risk.

Objective To explore the expression of long non-coding RNA hypoxia-inducible factor 1 alpha antisense RNA-1(lncRNA HIF1A-AS1)levels in placenta and cord blood of pregnant women with preeclampsia(PE)and its clinical significance.Methods Fifty pregnant women with PE who underwent cesarean section in Renji Hospital,Shanghai Jiaotong University School of Medicine from January 2020 to January 2022 were selected as the research subjects,including 24 pregnant women with mild PE and 26 pregnant women with severe PE.During the same period,25 healthy pregnant women who underwent cesarean section at the hospital were selected as the control group.The general data on the admission of all patients were collected.The real-time fluorescence quantitative qRT-PCR method was used to detect the expression level of lncRNA HIF1A-AS1 in pregnant women's placenta tissue and cord blood.The relationship between lncRNA HIF1A-AS1 level and pregnancy outcome was analyzed.The Pearson method was used to analyze the correlation between the relative expression level of lncRNA HIF1A-AS1 mRNA in placenta tissue and the level of lncRNA HIF1A-AS1 in cord blood.The receiver operating characteristic(ROC)curve was used to analyze the diagnostic value of lncRNA HIF1A-AS1 in placenta and cord blood for severe PE.Logistic regression was used to analyze the influencing factors of severe PE.Results Compared with the control group,the level of lncRNA HIF1A-AS1(2.76±0.36,1.83±0.29 vs 1.03±0.21)was elevated in the placental tissues of pregnant women with PE in the severe and mild groups(q=29.687,13.456),and the expression level of lncRNA HIF1A-AS1 in the severe group was higher than that in the mild group(q=15.792),and the differences were statistically significant(all P＜0.05).Compared with the control group,the level of lncRNA HIF1A-AS1(4.68±0.58,2.66±0.49 vs 1.06±0.34)was elevated in the cord blood of pregnant women with PE in the severe and mild groups(q=37.942,14.437),and the expression level of lncRNA HIF1A-AS1 in the severe group was higher than that in the mild group(q=20.951),and the differences were statistically significant(all P<0.05).The incidence of adverse pregnancy outcomes in placenta and cord blood lncRNA HIF1A-AS1 high expression group was significantly higher than that in lncRNA HIF1A-AS1 low expression group(χ2=7.714,5.773,all P<0.05).Pearson correlation analysis showed that the expression level of lncRNA HIF1A-AS1 mRNA in placenta tissue was positively correlated with the level of lncRNA HIF1A-AS1 in cord blood(r=0.546,P<0.05).ROC curve analysis showed that the area under the curve of lncRNA HIF1A-AS1 in the placenta for the diagnosis of severe PE was 0.788,with a sensitivity and a specificity of 80.80%and 80.00%,respectively.The AUC of lncRNA HIF1A-AS1 in the cord blood for the diagnosis of severe PE was 0.829,with a sensitivity and a specificity of 80.80%and 88.00%,respectively.Logistic regression analysis showed that 24-hour proteinuria,and placental and cord blood lncRNA HIF1A-AS1 levels were independent risk factors for severe PE(all P<0.05).Conclusion LncRNA HIF1A-AS1 in the placenta and cord blood of PE pregnant women is significantly up-regulated,and it increases with the aggravation of the disease.Placenta and cord blood lncRNA HIF1A-AS1 have a certain diagnostic value for the occurrence of severe PE.Detection of lncRNA HIF1A-AS1 has important significance for the early and accurate diagnosis of PE and the prediction of the disease.

Objective:To explore the applied effectiveness of the Skin and/or tissue,Education,Cooperation,Understanding,Report and Evaluate (SECURE) nursing pathway based on action research method in the prevention process of medical device-related pressure injuries (MDRPI) of patients in the Intensive Care Unit (ICU). Methods:The SECURE nursing pathway based on action research method included the establishment of a skin care team to identify problems,and the formulation of conducting intervention plan,and the development of targeting nursing interventions to prevent the occurrence of MDRPI. A total of 84 patients hospitalized in the ICU of Hebei General Hospital from March 2022 to March 2023 were selected,and they were randomly divided into a control group and an observation group,with 42 patients in each group. The control group implemented routine method to prevent MDRPI during ICU treatment,while the observation group implemented SECURE nursing pathway based on action research method to conduct prevention. The MDRPI incidence,the quality scores of ICU nursing,the scores of the Short Form Health Survey-36 (SF-36) of patients,the assessment of the improvement of MDRPI patients,and the satisfaction of patients for nursing care were compared between the two groups. Results:The MDRPI incidence during ICU treatment in the observation group was 4.76％ (2/42),which was significantly lower than that in the control group,with a statistically significant difference (x2=11.052,P<0.05). The average scores for device usage,prevention assessment,positioning management and preventive nursing after nursing intervention in the observation group were respectively (88.45±2.05),(89.36±2.11),(89.25±2.15) and (91.45±2.25),all of which were significantly higher than those in the control group,with statistically significant differences (t=11.425,12.052,10.052,13.478,P<0.05). After nursing intervention,the average scores for physical function,social function,psychological function and material life as the SF-36 scale in the observation group were (85.47±2.05),(86.48±2.05),(88.46±2.15) and (90.25±2.44),respectively,which were respectively higher than those in the control group,with statistically significant differences (t=12.414,11.045,10.252,10.478,P<0.05). The occurrence time,improvement time of wound and ICU treatment time of presenting MDRPI patients in the observation group were respectively (4.05±0.54) days,(3.45±0.15) days,and (8.12±2.14) days. Compared to the control group,the occurrence time of the observation group was longer,while both the improvement time of wound and ICU treatment time of the observation group were shorter,with statistically significant differences (t=8.485,10.012,13.001,P<0.05). The satisfaction degree of nursing care of patients in the observation group was 95.24％ (40/42),which was significantly higher than that in the control group (x2=12.054,P<0.05). Conclusion:The SECURE nursing pathway based on action research method,which prevents MDRPI of ICU patients,can reduce the MDRPI incidence rate of ICU patients,and enhance the work quality of nursing care for MDRPI. It is helpful to the recovery of ICU patients,which can also shorten the treatment time of ICU patients.

Purpose To explore the predictive value of intravoxel incoherent motion quantitative parameters and pathological grading for the survival prognosis of patients with hepatocellular carcinoma(HCC)after surgery.Materials and Methods A retrospective analysis was performed on 65 patients with HCC who had complete imaging data and underwent radical surgery at the Fourth Hospital of Hebei Medical University from October 2018 to November 2019.All patients were followed up for a 5-year survival period.The receiver operating characteristic curve was used to determine the optimal cut-off values for intravoxel incoherent motion quantitative parameters,including standard apparent diffusion coefficient(sADC),diffusion coefficient(D),pseudo-diffusion coefficient(D*)and perfusion fraction(F).Univariate and multivariate Cox regression analyses were performed to select independent predictive factors affecting the overall survival time of HCC patients after surgery.Results Univariate Cox regression analysis showed that pathological grading(HR=1.588,95%CI 0.936-2.692,P=0.086),microscopic vascular invasion(HR=2.512,95%CI 1.308-4.823,P=0.006),neutrophil-to-lymphocyte ratio(HR=1.752,95%CI 1.000-3.068,P=0.050),sADC(HR=0.433,95%CI 0.235-0.796,P=0.007),D(HR=0.262,95%CI 0.121-0.565,P<0.001)and F(HR=2.268,95%CI 1.259-4.087,P=0.006)were all prognostic factors.Multivariate Cox regression analysis showed that pathological grade(grade Ⅲ and Ⅳ)was the independent risk factor for the survival prognosis of patients after HCC surgery(HR=1.748,95%CI 1.003-3.045,P=0.049);the D value>0.916×10-3 mm2/s was the independent protective factor for their survival prognosis(HR=0.249,95%CI 0.113-0.550,P<0.001).Conclusion The pathological grade(Ⅲ/Ⅳ)as an independent risk factor and higher D values as a protective factor are the independent predictors of survival and prognosis of patients with HCC after surgery,and the combination of the two can provide a reference for clinical prognosis assessment.

Hematopoietic stem cell transplantation is currently the primary treatment for malignant hematologic diseases. However, due to complex factors, patients are prone to exhibiting multiple symptoms that interact to form symptom clusters, significantly impacting their quality of life and the outcomes of transplantation. This paper elaborates on the composition, evaluation tools, influencing factors, and nursing interventions of symptom clusters in hematopoietic stem cell transplant patients, aiming to provide guidance for the clinical management of symptom clusters in these patients.

Objective:To explore the applied effectiveness of the Skin and/or tissue,Education,Cooperation,Understanding,Report and Evaluate (SECURE) nursing pathway based on action research method in the prevention process of medical device-related pressure injuries (MDRPI) of patients in the Intensive Care Unit (ICU). Methods:The SECURE nursing pathway based on action research method included the establishment of a skin care team to identify problems,and the formulation of conducting intervention plan,and the development of targeting nursing interventions to prevent the occurrence of MDRPI. A total of 84 patients hospitalized in the ICU of Hebei General Hospital from March 2022 to March 2023 were selected,and they were randomly divided into a control group and an observation group,with 42 patients in each group. The control group implemented routine method to prevent MDRPI during ICU treatment,while the observation group implemented SECURE nursing pathway based on action research method to conduct prevention. The MDRPI incidence,the quality scores of ICU nursing,the scores of the Short Form Health Survey-36 (SF-36) of patients,the assessment of the improvement of MDRPI patients,and the satisfaction of patients for nursing care were compared between the two groups. Results:The MDRPI incidence during ICU treatment in the observation group was 4.76％ (2/42),which was significantly lower than that in the control group,with a statistically significant difference (x2=11.052,P<0.05). The average scores for device usage,prevention assessment,positioning management and preventive nursing after nursing intervention in the observation group were respectively (88.45±2.05),(89.36±2.11),(89.25±2.15) and (91.45±2.25),all of which were significantly higher than those in the control group,with statistically significant differences (t=11.425,12.052,10.052,13.478,P<0.05). After nursing intervention,the average scores for physical function,social function,psychological function and material life as the SF-36 scale in the observation group were (85.47±2.05),(86.48±2.05),(88.46±2.15) and (90.25±2.44),respectively,which were respectively higher than those in the control group,with statistically significant differences (t=12.414,11.045,10.252,10.478,P<0.05). The occurrence time,improvement time of wound and ICU treatment time of presenting MDRPI patients in the observation group were respectively (4.05±0.54) days,(3.45±0.15) days,and (8.12±2.14) days. Compared to the control group,the occurrence time of the observation group was longer,while both the improvement time of wound and ICU treatment time of the observation group were shorter,with statistically significant differences (t=8.485,10.012,13.001,P<0.05). The satisfaction degree of nursing care of patients in the observation group was 95.24％ (40/42),which was significantly higher than that in the control group (x2=12.054,P<0.05). Conclusion:The SECURE nursing pathway based on action research method,which prevents MDRPI of ICU patients,can reduce the MDRPI incidence rate of ICU patients,and enhance the work quality of nursing care for MDRPI. It is helpful to the recovery of ICU patients,which can also shorten the treatment time of ICU patients.

Purpose To evaluate the predictive value of left atrial appendage(LAA)morphological assessment by preoperative left atrial CT imaging in the risk of peri-device leak(PDL)after left atrial appendage occlusion(LAAO)in atrial fibrillation.Materials and Methods Seventy-one patients with atrial fibrillation who successfully underwent LAAO in Nanchong Central Hospital from January 2020 to February 2024 were retrospectively analyzed.According to the results of left atrial CT imaging after LAAO,all patients were divided into the PDL group(n=26)and the non-PDL group(n=45).The long diameter,short diameter,long diameter/short diameter ratio,area,perimeter of both the LAA orifice and landing area,and LAA length and LAA depth were compared between the two groups.Univariate and multivariate Logistic regression analysis were used to explore the risk factors leading to the differences between the two groups.Results The long diameter,long diameter/short diameter ratio,area,perimeter of both the LAA orifice and landing area in the PDL group were statistically higher than those in the non-PDL group(t/Z=4.952,-5.570,-2.912,3.191,6.757,-6.462,-3.318,3.733,all P<0.05).The LAA orifice short diameter,LAA length,LAA depth and the short diameter of landing area in the PDL group were higher than those in the non-PDL group,but there were no statistically significant differences between the two groups(t/Z=-1.773,1.765,1.509,-1.415,all P>0.05).Univariate Logistic regression analysis showed that the long diameter,long diameter/short diameter ratio,area and perimeter of LAA orifice and landing area before operation were correlated with postoperative PDL(P<0.05).Multivariate Logistic regression analysis showed that,the long diameter/short diameter ratio of LAA landing area was an independent risk factor for postoperative PDL.Conclusion Preoperative evaluation of the morphology of LAA orifice and landing zone by left atrial CT imaging can predict the occurrence of PDL after LAAO in atrial fibrillation in advance.When the long/short diameter of the landing area is large,it is necessary to be highly alert to the occurrence of PDL,which provides a basis for selecting and customizing the occluder before LAAO in patients with atrial fibrillation.

Objectives:The ORION-18 study has demonstrated that inclisiran can significantly reduce low-density lipoprotein cholesterol(LDL-C)and has good safety in Asian atherosclerotic cardiovascular disease(ASCVD)patients or ASCVD high-risk population.This subgroup analysis aims to further evaluate the efficacy and safety of inclisiran in Chinese mainland population.Methods:ORION-18 study is a multi-center,randomized,double-blind,placebo-controlled,phase Ⅲ clinical trial among Asian subjects,Chinese mainland subgroup included 232 ASCVD patients or ASCVD high-risk subjects who had already been treated with diet control and maximum tolerated doses of statins treatment(with or without other lipid-lowering treatments)but still had elevated LDL-C levels.Subjects were randomized in a 1:1 ratio to the inclisiran group and the placebo group(n=116 each),and received 300 mg of inclisiran or placebo respectively on day 0,90 and 270.The primary endpoint was the percentage change in LDL-C from baseline to day 330.The secondary endpoints included the time-adjusted percentage change and absolute change in LDL-C from baseline after day 90 and up to day 360,the absolute change in LDL-C from baseline to day 330,and the percentage changes from baseline to day 330 in proprotein convertase subtilisin/kexin type 9(PCSK9),total cholesterol,apolipoprotein B(ApoB),non-high-density lipoprotein cholesterol(non-HDL-C).Other secondary endpoints included the proportion of participants reaching LDL-C levels of<1.8 mmol/L at day 330,the proportion of participants with≥50%LDL-C reduction from baseline to day 330 and the proportion of participants who attained global lipid targets(the LDL-C target was<1.4 mmol/L for ASCVD patients and<1.8 mmol/L for ASCVD high-risk subjects)at day 330.Safety endpoints included adverse events during treatment,aboratory test abnormalities during treatment,serious adverse events,and assessed their severity and relation to treatment.Results:The inclisiran group showed a placebo-corrected percentage change in LDL-C from baseline to day 330 of-61.16%,and an absolute change of-1.73 mmol/L(both P<0.0001).Compared to the placebo group,the inclisiran group's time-adjusted percentage change in LDL-C from baseline between day 90 and day 360 was-58.51%,and an absolute change of was-1.64 mmol/L(both P<0.0001).At day 330,reductions from baseline were observed in the inclisiran group for PCSK9,total cholesterol,ApoB,non-HDL-C,with placebo-corrected percentage changes of-77.44%,-35.65%,-43.43%,-50.90%(all P<0.0001),respectively.At day 330,79.6%(74/93)of patients in the inclisiran group and 7.8%(6/77)in the placebo group achieved LDL-C levels<1.8 mmol/L,69.9%(65/93)of patients in the inclisiran group and 0%(0/77)in the placebo group achieved≥50%LDL-C reduction from baseline,66.7%(62/93)of patients in the inclisiran group and 2.6%(2/77)in the placebo group achieved their global LDL-C targets.The safety profile of inclisiran treatment over 12 months was comparable to that of the placebo,with no occurrence of treatment-related serious adverse events.Conclusions:In ASCVD patients or ASCVD high-risk subjects in Chinese mainland who have received diet control and maximum tolerable dose statins treatment(with or without other lipid-lowering treatments)and still have elevated LDL-C,inclisiran has a definite efficacy and good safety in reducing LDL-C.The efficacy and safety results of inclisiran assessed in Chinese mainland population are consistent with those of the general Asia population.

Hematopoietic stem cell transplantation is currently the primary treatment for malignant hematologic diseases. However, due to complex factors, patients are prone to exhibiting multiple symptoms that interact to form symptom clusters, significantly impacting their quality of life and the outcomes of transplantation. This paper elaborates on the composition, evaluation tools, influencing factors, and nursing interventions of symptom clusters in hematopoietic stem cell transplant patients, aiming to provide guidance for the clinical management of symptom clusters in these patients.